2021
DOI: 10.1016/j.bone.2020.115616
|View full text |Cite
|
Sign up to set email alerts
|

Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 25 publications
(17 citation statements)
references
References 26 publications
0
17
0
Order By: Relevance
“…Its mode of action is based on the inhibition of T-cell activation by binding to the costimulatory molecules CD80 and CD86 expressed by antigen-presenting cells such as DC. An interesting effect of abatacept is its capacity to inhibit the T-cell stimulatory capacities of osteoclasts differentiated from Mo-DC in the presence of M-CSF and RANKL [52]. Indeed, these DC-derived osteoclasts have the particularity of expressing MHC class II molecules as well as costimulatory molecules, and of retaining DC functions, such as the ability to stimulate T cells [52].…”
Section: Impact Of Targeted Therapies On Monocyte Differentiation Into Dendritic Cellsmentioning
confidence: 99%
See 1 more Smart Citation
“…Its mode of action is based on the inhibition of T-cell activation by binding to the costimulatory molecules CD80 and CD86 expressed by antigen-presenting cells such as DC. An interesting effect of abatacept is its capacity to inhibit the T-cell stimulatory capacities of osteoclasts differentiated from Mo-DC in the presence of M-CSF and RANKL [52]. Indeed, these DC-derived osteoclasts have the particularity of expressing MHC class II molecules as well as costimulatory molecules, and of retaining DC functions, such as the ability to stimulate T cells [52].…”
Section: Impact Of Targeted Therapies On Monocyte Differentiation Into Dendritic Cellsmentioning
confidence: 99%
“…An interesting effect of abatacept is its capacity to inhibit the T-cell stimulatory capacities of osteoclasts differentiated from Mo-DC in the presence of M-CSF and RANKL [52]. Indeed, these DC-derived osteoclasts have the particularity of expressing MHC class II molecules as well as costimulatory molecules, and of retaining DC functions, such as the ability to stimulate T cells [52]. So, by this double action on DC-derived osteoclasts, abatacept could prevent both osteoclastic bone resorption and aberrant activation of T cells.…”
Section: Impact Of Targeted Therapies On Monocyte Differentiation Into Dendritic Cellsmentioning
confidence: 99%
“…In vitro osteoclast formation of CD14 + blood monocytes from RA patients suggest pro-inflammatory monocytes differentiating into functional OCs in inflamed synovium [26]. Dendritic cells were also shown to be able to generate functional OCs [27,28], pointing out the potential contribution of various myeloid cells to functional osteoclasts in inflamed synovium. It is still not known if infiltrating cells in inflamed synovium fuse with cells, of maybe embryonic origin, that are already present in steady-state synovial tissue.…”
Section: Osteoclasts In Ramentioning
confidence: 96%
“…Studies showed that DCs can trans-differentiate to OCs in the presence of RANKL and macrophage colony-stimulating factor (M-CSF) ( Figure 2C ) ( 35 , 118 ). Another study suggested that activated DCs (bone-marrow-derived and splenic CD11c + cells) upon interaction with T helper-cells (CD4 + T cells or Th) can develop into functional OCs (TRAP + CT-R + cathepsin-k + ) in RANKL/RANK-dependent manner ( Figure 2C ) ( 119 ).…”
Section: Cells Of the Myeloid Lineagementioning
confidence: 99%